Spain to keep real drug prices confidential and draft conditional financing rules

Spain’s governing parties – the PP, PSOE and the Sumar alliance – have agreed on a parliamentary amendment that would make the actual prices paid for medicines reimbursed by the National Health System confidential. The proposal would bar the Ministry of Health, public authorities and pharmaceutical companies from revealing the final negotiated amounts, including any discounts that are not reflected in published list prices. The move comes as the Spanish Supreme Court reviews a case demanding transparency on the price of Novartis’ gene‑therapy drug Luxturna.

At the same time, a draft Royal Decree on drug financing is under public consultation. It would allow the Ministry of Health to approve conditional or provisional funding for new medicines or new indications for up to two years, extendable by one year, while additional clinical or economic evidence is gathered. The decree sets out specific criteria – unmet medical need, urgency for patients, and remaining uncertainties – and distinguishes between funding that is linked to evidence generation (conditional) and temporary funding pending a final decision (provisional). Both initiatives aim to protect negotiation leverage and manage budgetary risk while ensuring patient access to innovative treatments.